ReviewAmerican health & drug benefits2019
The Challenge of Managing Atopic Dermatitis in the United States.
Review in American health & drug benefits, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II.Frontiers in medicine · 2022Pooled it
- Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.American journal of clinical dermatology · 2021Trial
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.JAMA dermatology · 2020Trial
- Activation of MyD88/IRAK1 axis and downstream proinflammatory signaling in healthy adult and neonatal African American skin.JID innovations : skin science from molecules to population health · 2026Article
- Baricitinib 2 mg/day as a Cost-conscious Entry Point to Systemic Therapy in Moderate-to-severe Atopic Dermatitis: Real-world Data from a Japanese Clinic.Acta dermato-venereologica · 2025Article
- Therapeutic potential of cannabinoids for treating atopic dermatitis.Journal of cannabis research · 2025Review
- Saccharomyces boulardii (CNCM I-745) ameliorates Ovalbumin-induced atopic dermatitis by modulating the NF-κB signaling in skin and colon.Archives of dermatological research · 2025Article
- Associations Between Skin Microbiome and Metabolome in the Pathogenesis of Atopic Dermatitis Patients With Scalp Involvement.Allergy, asthma & immunology research · 2024Article
- Article
- Efficacy of a 3% Kānuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial.EClinicalMedicine · 2022Article
- Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting.Paediatric drugs · 2022Review
- Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.American journal of clinical dermatology · 2022Article
- Dermatology: how to manage atopic dermatitis in patients with skin of colour.Drugs in context · 2022Review
- Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada.Dermatology and therapy · 2021Article
- Interleukins 4 and 13 drive lipid abnormalities in skin cells through regulation of sex steroid hormone synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review.Dermatology and therapy · 2021Review
- Article
- Metformin ameliorates animal models of dermatitis.Inflammopharmacology · 2020Article
- 2-deoxy-d-glucose Ameliorates Animal Models of Dermatitis.Biomedicines · 2020Article
- Shikonin Inhibits Der p 2-Induced Cytokine and Chemokine Expression in Dendritic Cells in Patients with Atopic Dermatitis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis is a chronic inflammatory skin disease that affects up to 13% of children and 10% of adults in the United States. Among patients and their families, atopic dermatitis has a considerable effect on quality of life and represents a substantial economic burden.
objectiveTo describe the impact and challenges of atopic dermatitis and to provide nondermatologists in the healthcare community an enhanced understanding of atopic dermatitis to facilitate treatment and pharmacy benefit discussions. DISCUSSION: Atopic dermatitis is a heterogeneous disease, and its diagnosis is hampered by a lack of objective diagnostic criteria. The current management guidelines address the distinct clinical phenotypes as a single disease and do not incorporate recent clinical advances, such as the targeting of specific inflammatory processes. The treatment guidelines for atopic dermatitis are complex and challenge healthcare providers, patients, and caregivers. Novel treatments can provide additional therapeutic options for patients with atopic dermatitis.
conclusionsTreatment options for atopic dermatitis are expanding with the development of novel anti-inflammatory therapies. An increased understanding of these advancements is necessary to optimize care for patients with atopic dermatitis.
Indexed as
Identifiers
31057694PMC6485648W2980804201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.